- Home
- PROK vs YMAB Comparison
PROK vs YMAB Comparison
Compare PROK & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- YMAB
- Stock Information
- Founded
- PROK 2015
- YMAB 2015
- Country
- PROK United States
- YMAB United States
- Employees
- PROK N/A
- YMAB N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- YMAB Health Care
- Exchange
- PROK Nasdaq
- YMAB Nasdaq
- Market Cap
- PROK 334.8M
- YMAB 386.7M
- IPO Year
- PROK N/A
- YMAB 2018
- Fundamental
- Price
- PROK $2.45
- YMAB $8.61
- Analyst Decision
- PROK Buy
- YMAB Buy
- Analyst Count
- PROK 5
- YMAB 10
- Target Price
- PROK $6.25
- YMAB $13.91
- AVG Volume (30 Days)
- PROK 2.4M
- YMAB 842.3K
- Earning Date
- PROK 11-11-2025
- YMAB 11-07-2025
- Dividend Yield
- PROK N/A
- YMAB N/A
- EPS Growth
- PROK N/A
- YMAB N/A
- EPS
- PROK N/A
- YMAB N/A
- Revenue
- PROK $527,000.00
- YMAB $85,385,000.00
- Revenue This Year
- PROK $265.05
- YMAB N/A
- Revenue Next Year
- PROK N/A
- YMAB $13.97
- P/E Ratio
- PROK N/A
- YMAB N/A
- Revenue Growth
- PROK N/A
- YMAB N/A
- 52 Week Low
- PROK $0.46
- YMAB $3.55
- 52 Week High
- PROK $7.13
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- PROK 50.33
- YMAB 81.21
- Support Level
- PROK $2.12
- YMAB $8.50
- Resistance Level
- PROK $3.05
- YMAB $8.56
- Average True Range (ATR)
- PROK 0.23
- YMAB 0.02
- MACD
- PROK 0.03
- YMAB -0.13
- Stochastic Oscillator
- PROK 35.48
- YMAB 112.50
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.